Treatments
RNA drug corrects calcium signaling in chimeric model of Timothy syndrome
The drug, tested in rats that have human neurons, could enter clinical testing as early as next year, researchers say.
RNA drug corrects calcium signaling in chimeric model of Timothy syndrome
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
The facility’s institutional review board failed to report a 2021 incident and “serious and ongoing noncompliance” by a principal investigator, according to a letter released by the federal agency this week.
FDA describes ‘objectionable conditions’ at New York State Psychiatric Institute
A new look at walking in early childhood: Q&A with Rujuta Wilson
Quantifying toddlers’ gaits promises to improve autism diagnosis and intervention.
A new look at walking in early childhood: Q&A with Rujuta Wilson
Mutation in top autism-linked gene may alter eye reflex
The discovery could help clinicians diagnose children who carry mutations in the gene, called SCN2A, and gauge their responses to potential therapies.
Mutation in top autism-linked gene may alter eye reflex
New template streamlines sharing clinical trial results
This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.
New template streamlines sharing clinical trial results
Building bridges: Collaboration across the autism community
An autistic person and the mother of an autistic child explore partnership in the autism community.
Building bridges: Collaboration across the autism community
Journal club: Why do some children lose their autism diagnosis?
More than one-third of a cohort of autistic toddlers no longer meet criteria for the condition at school age, according to a new study, but the findings may not generalize because the cohort is predominantly white and affluent.
Journal club: Why do some children lose their autism diagnosis?
Uncertainty and excitement surround one company’s cell therapy for epilepsy
After 10 years of work, Neurona may have the data to quiet its skeptics. But its ongoing clinical trial will be the ultimate test.
Uncertainty and excitement surround one company’s cell therapy for epilepsy
Brian Boyd, classroom-based interventions and the importance of representation
The leader of the Frank Porter Graham Child Development Institute talks about what drew him into the autism field, and his departure from — and return to — the University of North Carolina at Chapel Hill.
Brian Boyd, classroom-based interventions and the importance of representation
Looking at eye tracking’s potential for clinical trials
This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.
Looking at eye tracking’s potential for clinical trials
Explore more from The Transmitter
Neuroscience needs a research-video archive
Video data are enormously useful and growing rapidly, but the field lacks a searchable, shareable way to store them.
Neuroscience needs a research-video archive
Video data are enormously useful and growing rapidly, but the field lacks a searchable, shareable way to store them.
Inclusivity committee disbands in protest at Canadian neuroscience institute
The majority of an 11-person committee resigned from the group this week following news that a staff position overseeing equity, diversity and inclusion would not be renewed.
Inclusivity committee disbands in protest at Canadian neuroscience institute
The majority of an 11-person committee resigned from the group this week following news that a staff position overseeing equity, diversity and inclusion would not be renewed.
How to explore your scientific values and develop a vision for your field
As a new professor, I was caught off guard by one part of the job: my role as an evaluator.
How to explore your scientific values and develop a vision for your field
As a new professor, I was caught off guard by one part of the job: my role as an evaluator.